Plus Therapeutics Inc (PSTV)

NASDAQ
Currency in USD
1.200
+0.020(+1.69%)
Real-time Data
PSTV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
1.1701.200
52 wk Range
0.9252.670
Key Statistics
Edit
Prev. Close
1.18
Open
1.17
Day's Range
1.17-1.2
52 wk Range
0.925-2.67
Volume
9.55K
Average Volume (3m)
47.93K
1-Year Change
-41%
Book Value / Share
-0.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PSTV Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
15.750
Upside
+1,212.50%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Plus Therapeutics Inc Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Compare PSTV to Peers and Sector

Metrics to compare
PSTV
Peers
Sector
Relationship
P/E Ratio
−0.5x−4.5x−0.7x
PEG Ratio
−0.01−0.120.00
Price/Book
−1.4x1.6x2.6x
Price / LTM Sales
1.2x12.1x3.1x
Upside (Analyst Target)
-160.6%49.4%
Fair Value Upside
Unlock9.0%8.9%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.750
(+1,212.50% Upside)

Earnings

Latest Release
Aug 16, 2023
EPS / Forecast
-- / -0.1225
Revenue / Forecast
-- / 1.13M
EPS Revisions
Last 90 days

FAQ

What Is the Plus Therapeutics (PSTV) Stock Price Today?

The Plus Therapeutics stock price today is 1.20

What Stock Exchange Does Plus Therapeutics Trade On?

Plus Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Plus Therapeutics?

The stock symbol for Plus Therapeutics is "PSTV."

What Is the Plus Therapeutics Market Cap?

As of today, Plus Therapeutics market cap is 7.08M.

What is Plus Therapeutics Earnings Per Share?

The Plus Therapeutics EPS is -2.22.

From a Technical Analysis Perspective, Is PSTV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.